A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2013; you can also visit the original URL.
The file type is application/pdf
.
How to design multi-target drugs
2007
Expert Opinion on Drug Discovery
Despite improved rational drug design and a remarkable progress in genomic, proteomic and highthroughput screening methods, the number of novel, single-target drugs fell much behind expectations during the past decade. Multi-target drugs and combinatorial therapies multiply the number of pharmacologically relevant target molecules by introducing a set of indirect, networkdependent effects. Parallel with this low-affinity binding of multi-target drugs eases the constraints of druggability, and
doi:10.1517/17460441.2.6.799
pmid:23488998
fatcat:gxlmf3t2yvddxm6rapf437pdf4